Grant: Engage Plus Grants Program
Université de Sherbrooke
$11,500.00
Development of robust and flexible assays for PARP-1
EF 2014-15
Résumé
This project is a continuation of our undoing partnership with CanAm Bioresearch (CanAm) on thedevelopment of poly(ADP ribose) polymerase 1 (PARP) inhibitors and assays. CanAm is developing a newclass of bi-functional pyridoxine-based molecules that block PARP and the vascular endothelial growth factorreceptor (VEGFR). Whereas PARP is involved in DNA repair, the VEGFR system participates inneo-vascularization of tumors. CanAm lacks expertise in enzymology and in PARP biology, which is anessential step to develop effective PARP-directed inhibitors. Our laboratory has extensive expertise in assayingenzymes and in developing biochemical tools to study them. Also, our currently NSERC-funded project(355388-10) involves the study of PARP. Therefore, a partnership with CanAm is a perfect fit in which we willprovide the much-needed expertise. The initial project (EGP 460794-13) has allowed us to establish anenzymatic assay for PARP and the screening of >200 molecules, including dozens of irreversible inhibitors,which constitute a new development for the project. Several molecules are promising hit to warrant deeperenzymological studies, which is ground for the first aim of this proposal. The second aim is similar to the onethat we initially proposed, which is to characterize hit molecules by assessing various aspect of PARP biology.For the project, CanAm will continue to provide series of PARP inhibitors and our group will perform theenzymological characterization. Our group has developed extensive expertise in working with enzymes,developing activation and inhibition assays, enzyme biochemistry and protein engineering. Therefore, we areperfectly suited to assist CanAm. By the same token, our group will benefit from the enrichment of ourexpertise in studying the fundamentals of PARP, a protein that interest us because of its role in apoptosis as asubstrate of caspases. This industry-academic partnership will strengthen the capability of CanAm to providenovel treatments and our ability to perform cutting edge research in biochemistry. This project will serve as astepping-stone for a more long-term collaboration between parties.
Programme
Engage Plus Grants Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
476588-2014
Name nom
Denault, JeanBernard
Department département
Pharmacologie
Organization id
68
Institution établissement
Université de Sherbrooke
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
11500
Program id
EGP2
Program name en
Engage Plus Grants Program
Program name fr
Programme de subvention d'engagement partenarial Plus
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Partie
1
Nb partie
1
Application title
Development of robust and flexible assays for PARP-1
Keyword
NSERC
Application summary
This project is a continuation of our undoing partnership with CanAm Bioresearch (CanAm) on thedevelopment of poly(ADP ribose) polymerase 1 (PARP) inhibitors and assays. CanAm is developing a newclass of bi-functional pyridoxine-based molecules that block PARP and the vascular endothelial growth factorreceptor (VEGFR). Whereas PARP is involved in DNA repair, the VEGFR system participates inneo-vascularization of tumors. CanAm lacks expertise in enzymology and in PARP biology, which is anessential step to develop effective PARP-directed inhibitors. Our laboratory has extensive expertise in assayingenzymes and in developing biochemical tools to study them. Also, our currently NSERC-funded project(355388-10) involves the study of PARP. Therefore, a partnership with CanAm is a perfect fit in which we willprovide the much-needed expertise. The initial project (EGP 460794-13) has allowed us to establish anenzymatic assay for PARP and the screening of >200 molecules, including dozens of irreversible inhibitors,which constitute a new development for the project. Several molecules are promising hit to warrant deeperenzymological studies, which is ground for the first aim of this proposal. The second aim is similar to the onethat we initially proposed, which is to characterize hit molecules by assessing various aspect of PARP biology.For the project, CanAm will continue to provide series of PARP inhibitors and our group will perform theenzymological characterization. Our group has developed extensive expertise in working with enzymes,developing activation and inhibition assays, enzyme biochemistry and protein engineering. Therefore, we areperfectly suited to assist CanAm. By the same token, our group will benefit from the enrichment of ourexpertise in studying the fundamentals of PARP, a protein that interest us because of its role in apoptosis as asubstrate of caspases. This industry-academic partnership will strengthen the capability of CanAm to providenovel treatments and our ability to perform cutting edge research in biochemistry. This project will serve as astepping-stone for a more long-term collaboration between parties.